Front of Mind: Psychiatry and Neurology News

Featured Post

EMERGENT-5 Side Effects Resembled Those in the 5-Week Trials

November 5, 2026

Long-term xanomeline-trospium side effects in schizophrenia resembled those in short-term trials, but the lack of a comparator limits interpretation.

Other top stories

Across 52 Weeks of Xanomeline-Trospium, Most Gastrointestinal Adverse Events Were First Reported by Week 8

November 5, 2026

Non-Drug Treatment for GAD: Cranial Electrotherapy Stimulation

October 25, 2026

Non-Drug Treatment for GAD: Mindfulness-Based Therapies

October 25, 2026

SUBSCRIBE TO OUR EMAIL

Get on the List

The latest news on Psychopharmacology

CYP2D6 Poor Metabolizer Status Tracks with Venlafaxine Treatment Failure in Two Real-World Cohorts

CYP2D6 Poor Metabolizer Status Tracks with Venlafaxine Treatment Failure in Two Real-World Cohorts

Smartphone-Delivered Therapy Improved Negative Symptoms of Schizophrenia Over 16 Weeks

Smartphone-Delivered Therapy Improved Negative Symptoms of Schizophrenia Over 16 Weeks

Adjunctive Lumateperone and Early CGI-S Improvement Were Associated With Response in Pooled MDD Trials

Adjunctive Lumateperone and Early CGI-S Improvement Were Associated With Response in Pooled MDD Trials

Could Psilocybin Help Parkinson’s Patients, Too?

Could Psilocybin Help Parkinson’s Patients, Too?

Other stories

Non-Drug Treatment Landscape for GAD: Cognitive Therapies

October 14, 2026

GAD Is More Common in Women, but Evidence Around Pregnancy and Menopause Remains Unclear

October 14, 2026

Negative Symptoms and Xanomeline-Trospium: What Trials and Practice Data Can and Cannot Show

October 5, 2026

Larger Response in Prominent Negative Symptoms, but No Evidence of Superiority

September 30, 2026

Two Investigational Paths in GAD: Company-Reported Results on DT120 ODT and SNTX-2643

September 29, 2026

Generalized Anxiety Disorder After 65: What the Screening Evidence Does and Does Not Cover

September 23, 2026

1 2 … 99 100 Older Posts